Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals has dropped an early-stage candidate for advanced cancers from its ...

More than three years after Deciphera Pharmaceuticals’ first approval, the company appears to be on the precipice of achieving a second commercial product. Oral tumor treatment vimseltinib passed the ...

Ono Pharmaceutical is expanding its scope in oncology with a $2.4 billion deal to buy Deciphera Pharmaceutical, a company that has one commercialized cancer therapy and a drug pipeline that includes a ...

(Reuters) -Deciphera Pharmaceuticals said on Monday Japan's Ono Pharmaceutical Co will acquire the cancer drugmaker for $2.4 billion to expand its oncology portfolio and presence in the United States ...

Ono Pharmaceutical of Japan said Monday it will acquire Deciphera Pharmaceuticals, a Boston-based maker of cancer drugs, for $2.4 billion. The all-cash deal values Diciphera at $25.60 per share, or a ...

Japanese biotech Ono Pharmaceutical is acquiring Deciphera Pharmaceuticals for $2.4 billion, the companies announced Monday. The move serves to bolster Ono’s cancer pipeline, with oncology pinpointed ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

Our estimates show that Qinlock 2L KIT exon 11+17/18 mutation indication sales guidance is unlikely to be achieved due to fractional incidence. Deciphera Pharmaceuticals is expecting a Phase III ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

Deciphera Pharmaceuticals Inc. said Monday it has agreed to be acquired by Japan’s Ono Pharmaceutical Co. Ltd in an all-cash deal valued at $2.4 billion. Under the terms of the deal, Ono JP:4528 will ...